Find Baricitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1187594-09-7, Olumiant, Incb028050, Ly3009104, 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, Incb 028050
Molecular Formula
C16H17N7O2S
Molecular Weight
371.4  g/mol
InChI Key
XUZMWHLSFXCVMG-UHFFFAOYSA-N
FDA UNII
ISP4442I3Y

Baricitinib
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.
Baricitinib is a Janus Kinase Inhibitor. The mechanism of action of baricitinib is as a Janus Kinase Inhibitor.
1 2D Structure

Baricitinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
2.1.2 InChI
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
2.1.3 InChI Key
XUZMWHLSFXCVMG-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
2.2 Other Identifiers
2.2.1 UNII
ISP4442I3Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-

2. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-, Phosphate (1:1)

3. Baricitinib Phosphate

4. Baricitinib Phosphate Salt

5. Incb-028050

6. Incb-28050

7. Incb028050

8. Ly-3009104

9. Ly3009104

10. Olumiant

2.3.2 Depositor-Supplied Synonyms

1. 1187594-09-7

2. Olumiant

3. Incb028050

4. Ly3009104

5. 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

6. Incb 028050

7. Incb-028050

8. Ly-3009104

9. 1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-3-azetidineacetonitrile

10. Baricitinib (ly3009104, Incb028050)

11. 2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile

12. Isp4442i3y

13. Ly 3009104

14. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-

15. Ly3009104 (phosphate);incb028050 (phosphate)

16. Incb28050

17. Baricitinib [usan]

18. Baricitinib [usan:inn]

19. Unii-isp4442i3y

20. Incb 28050

21. Olumiant (tn)

22. 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-

23. 3jw

24. Baricitinib [mi]

25. Baricitinib [inn]

26. Baricitinib [jan]

27. Baricitinib [who-dd]

28. Mls006011247

29. Schembl871150

30. Baricitinib (jan/usan/inn)

31. Baricitinib (ly3009104)

32. Baricitinib [ema Epar]

33. Baricitinib (incb028050)

34. Gtpl7792

35. Chembl2105759

36. Ammd00005

37. Chebi:95341

38. Baricitinib [orange Book]

39. Dtxsid30152228

40. Ex-a413

41. Hms3651l17

42. Hms3672m15

43. Hms3747g21

44. Bcp04686

45. Bdbm50021656

46. Mfcd21608464

47. Nsc799357

48. S2851

49. Zinc73069247

50. Akos022186127

51. Akos025401933

52. Am81232

53. Bcp9000380

54. Ccg-268312

55. Cs-0724

56. Db11817

57. Ds-7641

58. Nsc-799357

59. Pb27275

60. Sb10845

61. Ncgc00345839-01

62. Ncgc00345839-14

63. Ncgc00345839-16

64. 2-(3-(4-(3h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

65. Ac-27404

66. Hy-15315

67. Smr004703006

68. Bcp0726000031

69. Baricitinib (incb28050, Ly3009104)

70. Ft-0775037

71. Sw220096-1

72. D10308

73. A892931

74. J-503551

75. Q4860707

76. (1-(ethylsulfonyl)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)azetidin-3-yl)ethanenitrile

77. {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile

78. Incb 28050; Incb28050; Ly-3009104;1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-3-azetidineacetonitrile

2.4 Create Date
2009-09-28
3 Chemical and Physical Properties
Molecular Weight 371.4 g/mol
Molecular Formula C16H17N7O2S
XLogP3-0.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass371.11644398 g/mol
Monoisotopic Mass371.11644398 g/mol
Topological Polar Surface Area129 Ų
Heavy Atom Count26
Formal Charge0
Complexity678
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.


FDA Label


Rheumatoid arthritis

Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.

Atopic Dermatitis

Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.

Alopecia areata

Baricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. 1).


Treatment of chronic idiopathic arthritis (including rheumatoid arthritis , ankylosing spondylarthritis , psoriatic arthritis and juvenile idiopathic arthritis )


Treatment of Systemic Lupus Erythematosus (SLE)


Treatment of Coronavirus disease 2019


Treatment of alopecia areata


Treatment of atopic dermatitis


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Active Moiety
BARICITINIB
5.1.2 FDA UNII
ISP4442I3Y
5.1.3 Pharmacological Classes
Janus Kinase Inhibitors [MoA]; Janus Kinase Inhibitor [EPC]
5.2 ATC Code

L04AA37


L04AA37

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


L - Antineoplastic and immunomodulating agents

L04 - Immunosuppressants

L04A - Immunosuppressants

L04AA - Selective immunosuppressants

L04AA37 - Baricitinib


5.3 Absorption, Distribution and Excretion

Absorption

Baricitinib diaplays a dose-proportional increase in systemic exposure in the therapeutic dose range with linear pharmacokinetics. When orally administered, baricitinb is rapidly absorbed with an oral bioavailability of approximately 79 % (CV = 3.94 %). It has a median time to reach peak plasma concentration (Tmax) of 1hour (range: 0.5-3hours). Food consumption affects the exposure by decreasing it by up to 14 %, and decreasing the peak plasma concentration (Cmax) by up to 18 % and Tmax by 0.5 hours.


Route of Elimination

In a clinical pharmacology study, baricitinib was excreted predominately as the unchanged active substance in urine (69 %) and feces (15 %) and only 4 minor oxidative metabolites were identified (3 in urine; 1 in feces) constituting approximately 5 % and 1 % of the dose, respectively.


Volume of Distribution

Mean volume of distribution following intravenous infusion administration is 76 L.


Clearance

Mean apparent clearance (CL/F) in patients with rheumatoid arthritis is approximately 9.42 L/hr (CV = 34.3 %).


5.4 Metabolism/Metabolites

Baricitinib undergoes oxidation by CYP3A4, although less than 10% of the total dose is prone to this biotransformation. There is no formation of quantifiable metabolites in the plasma.


5.5 Biological Half-Life

Mean half-life in patients with rheumatoid arthritis is approximately 12.5 hrs (CV = 27.4 %).


5.6 Mechanism of Action

JAK enzymes are part of the family of tyrosine kinases that constitutively bind to the intracellular domains of cytokine receptors and promote the signalling cascades of cytokines and growth factors involved in haematopoiesis, inflammation and immune function that are also implicated in the pathogenesis of rheumatoid arthritis. Circulating proinflammatory cytokines bind to these cell surface receptors. Upon binding of extracellular cytokines and growth factors, JAKs are phosphorylated and activate signal transducers and activators of transcription (STATs). Through the signalling cascades, inflammatory cytokine and chemokine transcription is induced to form inflammatory mediators including IL-2, IL-6, IL-12, IL-15, IL-23, IFN- and GM-CSF. Baricitinib selectively and reversibly inhibits JAK1 and JAK2 to modulates their signalling pathways, thereby reducing the phosphorylation and activation of STATs. In isolated enzyme assays, baricitinib also exhibited an inhibitory effect on other types of JAK enzymes,Tyrosine Kinase 2 and JAK3, at higher concentrations needed for JAK1/2 inhibition.


API SUPPLIERS

read-more
read-more

01

Polpharma

Poland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Flag Poland
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF ASMF arrow-down AUDIT arrow-down
Polpharma CB

02

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

04

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB

05

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
CCSB Company Banner

06

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

07

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
TAPI Company Banner

08

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT arrow-down
blank

09

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT arrow-down
blank

10

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

Polpharma

Poland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Flag Poland
Digital Content Digital Content

Baricitinib

Registrant Name : Wooshin Labotach Co., Ltd.

Registration Date : 2025-07-28

Registration Number : Su579-5-ND

Manufacturer Name : Zakłady Farmaceutyczne Polp...

Manufacturer Address : Ul. Peplińska 19, Starogard Gdański, 83-200, Poland

Polpharma CB

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

Baricitinib

Registrant Name : Hiple Co., Ltd.

Registration Date : 2025-01-14

Registration Number : Su30-8-ND

Manufacturer Name : Chunghwa Chemical Synthesis ...

Manufacturer Address : No.1, Tung-Hsing St., Shu-Lin, New Taipei City 23850, Taiwan

CCSB Company Banner

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Aging Life Science Co., Ltd.

Registration Date : 2026-01-30

Registration Number : Su434-86-ND

Manufacturer Name : Apitoria Pharma Private Limi...

Manufacturer Address : Survey No. 10 & 13, Gaddapotharam Village, IDA, Kazipally, Jinnaram Mandal, Sangaredd...

blank

04

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Agerson Bio Co., Ltd.

Registration Date : 2024-04-03

Registration Number : Su163-32-ND(C)

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...

blank

05

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Polaris AI Pharma Co., Ltd.

Registration Date : 2025-11-13

Registration Number : Su163-32-ND(D)

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...

blank

06

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2024-07-26

Registration Number : Su163-32-ND(1)

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604&605, Rudraram (Village), Patancheru (Mandal), Sa...

blank

07

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2025-10-29

Registration Number : Su258-49-ND

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...

blank

08

Natco Pharma

India
RDD
Not Confirmed
arrow

Natco Pharma

India
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Toru Co., Ltd.

Registration Date : 2024-05-31

Registration Number : Su258-18-ND(A)

Manufacturer Name : Natco Pharma Limited

Manufacturer Address : Chemical Division Mekaguda Village, Nandigama Mandal Rangareddy District Telangana, 5...

blank

09

Natco Pharma

India
RDD
Not Confirmed
arrow

Natco Pharma

India
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2024-04-03

Registration Number : Su258-18-ND

Manufacturer Name : Natco Pharma Limited

Manufacturer Address : Chemical Division Mekaguda Village, Nandigama Mandal Rangareddy District Telangana, 5...

blank

10

Natco Pharma

India
RDD
Not Confirmed
arrow

Natco Pharma

India
arrow
RDD
Not Confirmed

Baricitinib

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2024-12-16

Registration Number : Su258-23-ND

Manufacturer Name : Natco Pharma Limited

Manufacturer Address : Chemical Division Mekaguda Village, Nandigama Mandal Rangareddy District Telangana, 5...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Polpharma

Poland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Flag Poland
Digital Content Digital Content

Baricitinib

About the Company : Polpharma API, a division of a leading Polish pharmaceutical group, has over 75 years of expertise in process development and cGMP manufacturing. Based at an FDA-approved site in C...

Polpharma API, a division of a leading Polish pharmaceutical group, has over 75 years of expertise in process development and cGMP manufacturing. Based at an FDA-approved site in Central Europe, it offers comprehensive API services from development to scale-up. Specializing in small molecule clinical candidates, Polpharma delivers customized, high-quality solutions with strong regulatory knowledge and advanced infrastructure. Globally recognized for complex chemistry, it is committed to precision, partnership, and progress. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Polpharma CB

02

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Baricitinib

About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Baricitinib

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Baricitinib

About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...

Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shanghai Minbiotech CB

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

Baricitinib

About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers cost-effective APIs with speed, supported by a skilled team. As the first Southeast Asian company to receive FDA approv...

Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers cost-effective APIs with speed, supported by a skilled team. As the first Southeast Asian company to receive FDA approval for synthetic and biotech APIs, CCSB has commercialized Statin, Immunosuppressant, Muscle Relaxant, and ACE Inhibitor APIs with complete DMF or COS. It partners with leading drug companies to develop and produce specialty APIs using advanced fermentation and synthesis technologies in Taiwan. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
CCSB Company Banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Baricitinib

About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...

Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Omgene Company Banner

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Baricitinib

About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...

Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios with over 350 products, alongside tailored CDMO services. Leveraging deep expertise and diverse technologies, we deliver flexible, high-quality solutions to meet our partners’ needs. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
TAPI Company Banner

08

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

About the Company : Anhui Haikang Pharmaceutical Co., Ltd. was established in 2009 and located in a High-tech industry park, Anqing City, Anhui Province---a famous historical and cultural city in Chin...

Anhui Haikang Pharmaceutical Co., Ltd. was established in 2009 and located in a High-tech industry park, Anqing City, Anhui Province---a famous historical and cultural city in China, adjacent to SINOPEC Anqing Branch. This industry park has been declared as a national chemical industry park, providing a strong impetus and solid guarantee for the future development of us. As a production base, Anhui Haikang provides sufficient high-quality pharmaceutical and chemical products.
blank

09

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

About the Company : Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 years of development, ...

Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 years of development, Nanfang Pharmaceutical has grown into a major domestic manufacturer of anti-tumor raw materials and intermediates, and has expanded to non-anti-tumor drugs. Using the company's accumulated rich experience and first-class technology in plant extraction, the company's product line has been expanded to the field of plant-derived products.
blank

10

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Baricitinib

About the Company : Guangzhou Green Cross Pharmaceutical is a leading Chinese manufacturer of amino acid injection formulations and a full-service provider of high-end parenteral nutrition and generic...

Guangzhou Green Cross Pharmaceutical is a leading Chinese manufacturer of amino acid injection formulations and a full-service provider of high-end parenteral nutrition and generic drugs. Among the first GMP-certified pharmaceutical companies in China, we have grown into a comprehensive group with integrated R&D, production, and sales. Our operations include one R&D center and five manufacturing bases for APIs and formulations.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

The drug Olumiant (baricitinib) has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults.


Lead Product(s): Baricitinib,Remdesivir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Olumiant

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 11, 2021

Dr Reddy Company Banner

01

Lead Product(s) : Baricitinib,Remdesivir

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Eli Lilly

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : The drug Olumiant (baricitinib) has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospita...

Product Name : Olumiant

Product Type : Miscellaneous

Upfront Cash : Undisclosed

May 11, 2021

Dr Reddy Company Banner
  • Development Update

Details:

Baricitinib is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of dengue.


Lead Product(s): Baricitinib,Dexamethasone,Acetylcysteine

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: University of Oxford

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 21, 2026

blank

02

Oxford University Clinical Research Unit, Vietnam

Country
arrow
RDD
Not Confirmed

Oxford University Clinical Research Unit, Vietnam

Country
arrow
RDD
Not Confirmed

Details : Baricitinib is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of dengue.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 21, 2026

blank
  • Development Update

Details:

Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Polymyalgia Rheumatica.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Musculoskeletal Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Eli Lilly

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 12, 2025

blank

03

University Hospital, Brest

Country
arrow
RDD
Not Confirmed

University Hospital, Brest

Country
arrow
RDD
Not Confirmed

Details : Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Polymyalgia Rheumatica.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 12, 2025

blank

Details:

Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 29, 2025

blank

04

Eli Lilly

U.S.A
arrow
RDD
Not Confirmed

Eli Lilly

U.S.A
arrow
RDD
Not Confirmed

Details : Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 29, 2025

blank

Details:

Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 29, 2025

blank

05

Eli Lilly

U.S.A
arrow
RDD
Not Confirmed

Eli Lilly

U.S.A
arrow
RDD
Not Confirmed

Details : Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 29, 2025

blank
  • Development Update

Details:

Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of HIV Infections.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Eli Lilly

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 06, 2025

blank

06

Gabrail Cancer Center Research

Country
arrow
RDD
Not Confirmed

Gabrail Cancer Center Research

Country
arrow
RDD
Not Confirmed

Details : Baricitinib is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of HIV Infections.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 06, 2025

blank
  • Development Update

Details:

Baricitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoidosis.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Eli Lilly

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2025

blank

07

Stanford University

Country
arrow
RDD
Not Confirmed

Stanford University

Country
arrow
RDD
Not Confirmed

Details : Baricitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sarcoidosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 10, 2025

blank

Details:

Olumiant (baricitinib) is an oral JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Olumiant

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 08, 2025

blank

08

Eli Lilly

U.S.A
arrow
RDD
Not Confirmed

Eli Lilly

U.S.A
arrow
RDD
Not Confirmed

Details : Olumiant (baricitinib) is an oral JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata.

Product Name : Olumiant

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 08, 2025

blank
  • Development Update

Details:

Baricitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia Areata.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Eli Lilly

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 28, 2025

blank

09

National Taiwan University Hospital

Country
arrow
RDD
Not Confirmed

National Taiwan University Hospital

Country
arrow
RDD
Not Confirmed

Details : Baricitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alopecia Areata.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 28, 2025

blank

Details:

The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.


Lead Product(s): Baricitinib,Inapplicable

Therapeutic Area: Immunology Brand Name: Olumiant

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 04, 2024

blank

10

Eva Pharma

Egypt
arrow
RDD
Not Confirmed

Eva Pharma

Egypt
arrow
RDD
Not Confirmed

Details : The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.

Product Name : Olumiant

Product Type : Miscellaneous

Upfront Cash : Undisclosed

September 04, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1187594-09-7 / Baricitinib API manufacturers, exporters & distributors?

Baricitinib manufacturers, exporters & distributors 1

23

PharmaCompass offers a list of Baricitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Baricitinib manufacturer or Baricitinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Baricitinib manufacturer or Baricitinib supplier.

API | Excipient name

Baricitinib

Synonyms

1187594-09-7, Olumiant, Incb028050, Ly3009104, 2-(3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, Incb 028050

Cas Number

1187594-09-7

Unique Ingredient Identifier (UNII)

ISP4442I3Y

About Baricitinib

Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- Manufacturers

A 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-, including repackagers and relabelers. The FDA regulates 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- Suppliers

A 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- supplier is an individual or a company that provides 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- active pharmaceutical ingredient (API) or 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- finished formulations upon request. The 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- suppliers may include 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- API manufacturers, exporters, distributors and traders.

click here to find a list of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- USDMF

A 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- DMF (Drug Master File) is a document detailing the whole manufacturing process of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- active pharmaceutical ingredient (API) in detail. Different forms of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- DMFs exist exist since differing nations have different regulations, such as 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- DMF submitted to regulatory agencies in the US is known as a USDMF. 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- USDMF includes data on 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- suppliers with USDMF on PharmaCompass.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- Drug Master File in Korea (3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-. The MFDS reviews the 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- KDMF as part of the drug registration process and uses the information provided in the 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- KDMF to evaluate the safety and efficacy of the drug.

After submitting a 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- API can apply through the Korea Drug Master File (KDMF).

click here to find a list of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- suppliers with KDMF on PharmaCompass.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- WC

A 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- written confirmation (3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- WC) is an official document issued by a regulatory agency to a 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- manufacturer, verifying that the manufacturing facility of a 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- APIs or 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- finished pharmaceutical products to another nation, regulatory agencies frequently require a 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- WC (written confirmation) as part of the regulatory process.

click here to find a list of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- suppliers with Written Confirmation (WC) on PharmaCompass.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- suppliers with NDC on PharmaCompass.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- GMP

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- GMP manufacturer or 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- GMP API supplier for your needs.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- CoA

A 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- CoA (Certificate of Analysis) is a formal document that attests to 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-'s compliance with 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- specifications and serves as a tool for batch-level quality control.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- CoA mostly includes findings from lab analyses of a specific batch. For each 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- may be tested according to a variety of international standards, such as European Pharmacopoeia (3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- EP), 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- JP (Japanese Pharmacopeia) and the US Pharmacopoeia (3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]- USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty